YUTOPAR Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Yutopar, and when can generic versions of Yutopar launch?

Yutopar is a drug marketed by Astrazeneca and is included in two NDAs.

The generic ingredient in YUTOPAR is ritodrine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the ritodrine hydrochloride profile page.

Summary for YUTOPAR

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	1
Patent Applications:	2
Formulation / Manufacturing:	see details
DailyMed Link:	YUTOPAR at DailyMed

Drug patent expirations by year for YUTOPAR

Recent Clinical Trials for YUTOPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cairo University	Phase 4

See all YUTOPAR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for YUTOPAR

G02CA	Sympathomimetics, labour repressants
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for YUTOPAR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-002	Sep 27, 1984		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astrazeneca	YUTOPAR	ritodrine hydrochloride	TABLET;ORAL	018555-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for YUTOPAR

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	YUTOPAR	ritodrine hydrochloride	TABLET;ORAL	018555-001	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-001	Approved Prior to Jan 1, 1982	⤷ Try a Trial	⤷ Try a Trial
Astrazeneca	YUTOPAR	ritodrine hydrochloride	INJECTABLE;INJECTION	018580-002	Sep 27, 1984	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for YUTOPAR

See the table below for patents covering YUTOPAR around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Spain	309809		⤷ Try a Trial
Austria	268252		⤷ Try a Trial
Germany	1293782	1-(4-Hydroxyphenyl)-2-[2-(4-hydroxyphenyl)-aethylamino]-propanol, dessen physiologisch vertraeglichen Salze und Verfahren zu deren Herstellung	⤷ Try a Trial
United Kingdom	1111451		⤷ Try a Trial
Austria	264502		⤷ Try a Trial
France	4404		⤷ Try a Trial
France	1483718	Nouvelle aralkylamine et sa préparation	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for YUTOPAR

Recent Clinical Trials for YUTOPAR

Anatomical Therapeutic Chemical (ATC) Classes for YUTOPAR

Make Better Decisions: Try a trial or see plans & pricing